Evidence map›Paper›PMID 36424638›Full record

ArticleArthritis research & therapy2022

Autologous hematopoietic stem cell transplantation improves long-term survival-data from a national registry.

Norbert Blank, Marc Schmalzing, Pia Moinzadeh, Max Oberste, Elise Siegert, Ulf Müller-Ladner, Gabriela Riemekasten, Claudia Günther, Ina Kötter, Gabriele Zeidler and 16 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Arthritis research & therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 9 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Stem cell therapy in systemic sclerosis.Clinical rheumatology · 2025
    Review
  5. Article
  6. [Systemic sclerosis].Dermatologie (Heidelberg, Germany) · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors at 18 institutions in 1 country.

Norbert BlankInternal Medicine 5, Division of Hematology, Oncology and Rheumatology, Department of Rheumatology, University Hospital Heidelberg, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany. norbert.blank@med.uni-heidelberg.de.
Marc SchmalzingDepartment of Rheumatology/Clinical Immunology, University Hospital Wuerzburg, Wuerzburg, Germany.
Pia MoinzadehDepartment of Dermatology and Venereology, University Hospital Cologne, Cologne, Germany.
Max ObersteInstitute of Medical Statistics and Computational Biology, Faculty of Medicine, University of Cologne, Cologne, Germany.
Elise SiegertDepartment of Rheumatology, Charité Universitätsmedizin Berlin, Berlin, Germany.
Ulf Müller-LadnerCampus Kerckhoff, Department of Rheumatology and Clinical Immunology, Justus Liebig University Giessen, Bad Nauheim, Germany.
Gabriela RiemekastenDepartment of Rheumatology, University Medical Center-UKSH, Luebeck, Germany.
Claudia GüntherDepartment of Dermatology, University Hospital Carl Gustav Carus, Dresden, Germany.
Ina KötterDepartment of Rheumatology and Immunology, University Hospital, Hamburg-Eppendorf and Rheumatology Hospital Bad Bramstedt, Bad Bramstedt, Germany.
Gabriele ZeidlerDepartment of Rheumatology, Johanniter-Krankenhaus im Flaeming Treuenbrietzen, Treuenbrietzen, Germany.
Christiane PfeifferDepartment of Dermatology, University Hospital Munich, Munich, Germany.
Aaron JucheDepartment of Rheumatology, Immanuel Krankenhaus Berlin-Buch, Berlin, Germany.
Ilona JandovaDepartment of Rheumatology, University Hospital Freiburg, Freiburg im Breisgau, Germany.
Jan EhrchenDepartment of Dermatology and Venerology, University Hospital Muenster, Muenster, Germany.
Laura SusokDepartment of Dermatology and Venereology, Ruhr-University-Bochum, Bochum, Germany.
Tim SchmeiserDepartment of Dermatology, St. Josef Hospital Wuppertal, Wuppertal, Germany.
Cord SunderkötterDermatology, University Hospital Halle, Halle, Germany.
Jörg H W DistlerDepartment of Rheumatology, University Hospital Erlangen, Erlangen, Germany.
Margitta WormDepartment of Dermatology and Allergology, Charité Universitätsmedizin Berlin, Berlin, Germany.
Alexander KreuterAllergology, HELIOS St. Elisabeth Hospital Oberhausen, University Witten-Herdecke, Witten, Germany.
Gernot KeyßerRheumatology, University Hospital Halle, Halle, Germany.
Hanns-Martin LorenzInternal Medicine 5, Division of Hematology, Oncology and Rheumatology, Department of Rheumatology, University Hospital Heidelberg, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany.
Thomas KriegDepartment of Dermatology and Venereology, University Hospital Cologne, Cologne, Germany.
Nicolas HunzelmannDepartment of Dermatology and Venereology, University Hospital Cologne, Cologne, Germany.
Jörg HenesCentre for Interdisciplinary Clinical Immunology, Rheumatology and Auto-inflammatory Diseases and Department of Internal Medicine II (Oncology, Hematology, Immunology, Rheumatology), University Hospital Tuebingen, Tuebingen, Germany.
German Network for Systemic Sclerosis
University Hospital Cologne · DECharité - Universitätsmedizin Berlin · DEHeidelberg University · DEUniversity Hospital in Halle · DEHELIOS St. Elisabeth Klinik Oberhausen · DEImmanuel Krankenhaus · DEKlinik Preetz · DEMünchen Klinik · DERuhr University Bochum · DESt. Josef-Hospital · DEUniversitätsklinikum Erlangen · DEUniversitätsklinikum Würzburg · DEUniversity Hospital Carl Gustav Carus · DEUniversity Hospital Münster · DEUniversity Medical Center Freiburg · DEUniversity Medical Center Hamburg-Eppendorf · DEUniversity of Cologne · DEUniversity of Giessen · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCurrent recommendations on the management of systemic sclerosis (SSc) suggest that autologous hematopoietic stem cell therapy (HSCT) can be a rescue therapy for patients with rapidly progressive SSc.

objectivesTo assess the safety and efficacy of HSCT for patients with SSc and to compare these with non-HSCT patients in a control cohort with adjusted risk factors.

methodsA retrospective analysis of data from the multicentric German network for systemic scleroderma (DNSS) with 5000 patients with SSc. Control groups consisted of all patients with diffuse cutaneous (dc)-SSc (group A) and an adjusted high-risk cohort of male patients with Scl70-positive dc-SSc (group B).

resultsEighty SSc patients received an HSCT 4.1 ± 4.8 years after SSc diagnosis. Among them, 86.3% had dc-SSc, 43.5% were males, and 71.3% were positive for Scl70 antibodies. The control group A (n=1513) showed a significant underrepresentation of these risk factors for mortality. When the survival of the control group B (n=240) was compared with the HSCT group, a lower mortality of the latter was observed instead. Within 5 years after HSCT, we observed an improvement of the mRSS from 17.6 ± 11.5 to 11.0 ± 8.5 (p=0.001) and a stabilization of the DLCO. We did not see differences in transplant-related mortality between patients who received HSCT within 3 years after SSc diagnosis or later.

conclusionOur analysis of real-life data show that the distribution of risk factors for mortality is critical when HSCT cohorts are compared with non-HSCT control groups.

Indexed as

Hematopoietic Stem Cell TransplantationScleroderma, DiffuseScleroderma, SystemicFemaleHumansMaleRegistriesRetrospective StudiesTransplantation, AutologousAutologous hematopoietic stem cell transplantationGerman network for systemic sclerodermaSclerodermaSystemic sclerosis

Identifiers

PMID36424638
PMCPMC9685870
OpenAlexW4309889374

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.